What is Ozempic Butt?

By 
Dr Amit Kumar Singh
 on 
Jul 4, 2025
 • 
5
 min read

Managing weight can be a challenging journey, especially when dealing with the physical and emotional toll it often brings. For many, Ozempic and other GLP-1 medications, like Wegovy and Mounjaro have become a beacon of hope in this battle. Originally developed to manage blood sugar in type 2 diabetes, Ozempic is now widely recognised for its effectiveness in aiding weight loss. By suppressing appetite, regulating blood sugar levels, and slowing gastric emptying, this GLP-1 agonist helps individuals achieve and sustain significant weight loss. For those who have struggled with conventional methods, Ozempic offers a new and effective tool to regain control over their health. 

As with any medication, Ozempic and similar medications come with potential side effects—some of which have sparked widespread discussion. One such concern is the term "Ozempic butt," which refers to a loss of fat in areas like the buttocks, leading to a sagging or deflated appearance. This effect is not unique to Ozempic but is associated with significant and rapid weight loss in general. As the body sheds fat, it can redistribute unevenly, potentially leaving some areas with less volume than before. Understanding this phenomenon is key to managing expectations and addressing concerns. 

Understanding "Ozempic Butt"

"Ozempic butt" is a colloquial term that refers to a specific side effect experienced by some individuals using GLP-1 receptor agonists. This phenomenon occurs as a result of rapid weight loss associated with the medication, leading to changes in the appearance and texture of the buttocks.

Physical Characteristics of "Ozempic Butt"

The term "Ozempic butt" describes several physical characteristics that can manifest in individuals who experience significant weight loss while on GLP-1 agonists:

  1. Sagging Skin: One of the most notable features of "Ozempic butt" is the sagging or loose skin in the buttocks area. As individuals lose weight quickly, the skin may not have enough time to adjust to the new body shape, resulting in a less firm appearance. This condition is often referred to as buttock ptosis, where the gluteal tissue droops below the natural crease between the legs and buttocks.
  2. Deflation Appearance: Many users report that their buttocks appear "deflated" or flattened after losing fat. This change can occur because weight loss affects fat distribution throughout the body, including in the buttocks and thighs. As fat diminishes, the underlying tissue may not provide sufficient volume or support, leading to a less contoured look.
  3. Wrinkling and Loose Skin: In addition to sagging, some individuals may notice wrinkling or excess skin that hangs down. This is particularly common in those who have experienced significant weight loss, as skin elasticity can diminish with age or rapid changes in body weight. A study highlighted that skin elasticity varies among individuals, influencing how well skin can adapt to changes in body composition.
  4. Lipodystrophy: Some users may also experience lipodystrophy, a condition characterised by abnormal fat distribution in the body. This can result in fat being redistributed to other areas while causing loss of volume in the buttocks.

Potential Causes of "Ozempic Butt"

Understanding the underlying causes of this phenomenon involves examining how GLP-1 agonists influence fat distribution and the hormonal changes they induce. The potential causes are as follows:

A. Redistribution of Fat

GLP-1 receptor agonists have been shown to affect body fat distribution, particularly by promoting weight loss and altering the way fat is stored in the body. Research indicates that these medications can lead to a preferential loss of visceral fat (the fat stored around internal organs) while potentially redistributing subcutaneous fat (the fat located under the skin). Mechanisms behind redistribution is as follows:

Lipolysis Enhancement

GLP-1 RAs increase lipolysis, the process by which stored fat is broken down into fatty acids for energy. This effect is mediated through increased sympathetic nervous system activity, which enhances fat mobilisation from adipose tissue. As visceral fat decreases, there may be a relative increase in subcutaneous fat, particularly in areas like the buttocks and thighs.

Browning of Adipose Tissue

Some studies suggest that GLP-1 agonists may promote the browning of white adipose tissue (WAT), which is associated with improved metabolic health. Browning refers to the process where white fat cells acquire characteristics similar to brown fat cells, leading to increased energy expenditure and altered fat storage patterns. This can result in changes to how and where fat is deposited in the body, potentially contributing to the appearance of "Ozempic butt".

A study exploring liraglutide's effects on body composition found that treatment led to changes in lipid metabolism and a redistribution of body fat, particularly enhancing subcutaneous fat browning. This suggests that while overall weight loss occurs, specific areas may retain or even gain fat relative to others, contributing to the physical characteristics associated with "Ozempic butt."

B. Hormonal Changes

GLP-1 receptor agonists also influence hormonal levels that are critical for regulating metabolism and fat distribution.

Insulin Sensitivity Improvement

By enhancing insulin sensitivity, GLP-1 agonists help regulate glucose levels and reduce insulin resistance. Improved insulin sensitivity can lead to better lipid metabolism and reduced ectopic fat accumulation, which is often linked to increased cardiovascular risk. When insulin sensitivity improves, the body may become more efficient at utilising fats for energy rather than storing them excessively.

Effects on Appetite-Regulating Hormones

GLP-1 agonists also play a role in appetite regulation by affecting hormones such as leptin and ghrelin. Increased levels of GLP-1 lead to decreased appetite and increased satiety, which can contribute to weight loss. However, changes in these hormones can also influence where fat is stored in the body. For instance, an increase in leptin levels (which signals fullness) may alter how the body distributes remaining fat stores after weight loss.

A study highlighted that GLP-1 agonists not only improve glycemic control but also have significant effects on lipid metabolism and hormonal balance . These changes can help mitigate some of the adverse effects associated with obesity while altering how and where body fat is distributed

Addressing Concerns and Managing Side Effects of "Ozempic Butt"

Consulting with a Healthcare Provider

Discussing concerns about "Ozempic butt" with a healthcare professional is crucial for anyone experiencing this side effect. A healthcare provider can offer personalised advice and guidance tailored to individual health needs. They can help assess the extent of the changes and recommend strategies for managing side effects effectively.

  1. Personalised Assessment: Healthcare providers can evaluate the specific characteristics of "Ozempic butt," such as loosening of skin or changes in fat distribution, and determine whether these changes are within a normal range for someone undergoing rapid weight loss. They can also discuss potential underlying factors contributing to these changes, such as age, skin elasticity, and overall body composition.
  2. Guidance on Management: Providers may suggest various approaches to mitigate the effects of "Ozempic butt," including strength training exercises to build muscle in the gluteal region, which can help improve appearance and firmness. Additionally, they may recommend dietary adjustments or skincare routines that promote skin elasticity and hydration.

Lifestyle Modifications

Incorporating dietary and exercise strategies can significantly impact body composition and help manage the appearance of "Ozempic butt."

1. Dietary Strategies:

Consuming a balanced diet that includes adequate protein can support muscle maintenance and growth during weight loss. A study found that higher protein intake is associated with better preservation of lean mass during weight loss, which is essential for maintaining a toned appearance. Staying hydrated is crucial for skin health. Proper hydration can improve skin elasticity and reduce the appearance of sagging skin. Incorporating foods rich in omega-3 fatty acids, such as salmon and walnuts, may also support skin health.

2. Exercise Strategies:

Engaging in regular strength training exercises targeting the gluteal muscles can help counteract some of the effects of weight loss on body shape. Exercises such as squats, lunges, and deadlifts are effective for building muscle in this area. Research indicates that resistance training not only helps improve body composition but also enhances overall metabolic health. Working with a registered dietitian or fitness trainer can provide additional support in developing personalised meal plans and exercise regimens that align with individual goals. These professionals can offer tailored strategies that consider any unique challenges posed by GLP-1 therapy.

Long-Term Considerations

Understanding the potential long-term effects of GLP-1 agonists on body composition is essential for those considering or currently using these medications.

  1. Long-Term Effects on Body Composition: While GLP-1 RAs are effective for weight management, it is important to recognize that rapid weight loss can lead to changes in body fat distribution and skin elasticity over time. Research indicates that significant weight loss often results in loose  skin due to reduced fat volume beneath the skin. This is not unique to GLP-1 agonists but occurs with any substantial weight loss.
  2. Maintaining a Healthy Lifestyle Post-Medication: Even after discontinuing GLP-1 therapy, maintaining a healthy lifestyle remains crucial for sustaining weight loss and overall health. Continuing to engage in regular physical activity and adhering to a balanced diet can help manage body composition effectively over time.
  3. Consultation for Ongoing Support: Regular follow-ups with healthcare providers after stopping medication are important for monitoring any long-term effects on body composition and addressing new concerns as they arise.

Conclusion

The phenomenon known as "Ozempic butt," describes the skin sagging or deflated appearance of the buttocks that some individuals may experience after significant weight loss while using GLP-1 receptor agonists like Wegovy or Mounjaro. For example, studies indicate that GLP-1 agonists can lead to changes in fat distribution, resulting in less padding in the buttocks and potentially contributing to a less firm appearance. It is essential for individuals experiencing concerns about "Ozempic butt" to consult with a healthcare provider for personalised advice and guidance. 

Healthcare professionals can assess individual circumstances, provide strategies for managing side effects, and recommend appropriate lifestyle modifications to maintain body composition. By prioritising both health and aesthetic concerns, individuals can navigate their weight loss journey more effectively while minimising the potential side effects associated with GLP-1 therapy. 

FAQs

1. Can Ozempic Butt be prevented?
Yes, while complete prevention might not be possible, engaging in strength training exercises focused on the glutes, like squats or lunges, can help build muscle in the area and maintain its shape during weight loss. A balanced diet with adequate protein also supports muscle health.

2. Is Ozempic Butt permanent?
Not necessarily. The appearance of the Ozempic Butt can improve with time if muscle mass is rebuilt through targeted exercises. Once weight stabilises, incorporating fitness routines that focus on the glutes can help regain a firmer and fuller look.

3. Should I stop taking GLP-1 if I experience Ozempic Butt?
Not usually. Ozempic is an effective medication for managing weight and/or type 2 diabetes. If you're concerned about changes in your body shape, discuss them with your healthcare provider. They may suggest adjustments to your fitness or dietary routine to address these side effects.

References

  1. Huang, C., Zhang, Y., Wang, Y., & Li, J. (2024). The emerging role of GLP-1 receptor agonists in managing cardiovascular and metabolic diseases. Frontiers in Pharmacology, 15, Article PMC10866919 https://pmc.ncbi.nlm.nih.gov/articles/PMC10866919/ 
  2. Novo Nordisk. (2024). Important Safety Information for Ozempic® (semaglutide). Retrieved from https://www.ozempic.com/important-safety-information.html
  3. Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2023). Once-Weekly Semaglutide in Adults without Diabetes and with Overweight or Obesity.https://www.nejm.org/doi/full/10.1056/NEJMoa2307563#:~:text=Semaglutide%2C%20a%20long%2Dacting%20analogue%20of%20GLP%2D1%2C%20administered,or%20obesity%20who%20did%20not%20have%20diabetes
  4. Reliant Medical Group. (2023). Medical Mythbuster: Is “Ozempic Butt” an Actual Medical Problem? Reliant Medical Group Blog. Retrieved from https://reliantmedicalgroup.org/blog/2023/06/26/medical-mythbuster-is-ozempic-butt-an-actual-medical-problem/
  5. Friedrich, M. J. (2023). Rapid weight and fat loss associated with GLP-1 receptor agonists and the potential impact on the face. https://pubmed.ncbi.nlm.nih.gov/37541662/
  6. Li, H., Liu, Y., Sun, H., Li, X., & Zhang, Y. (2023). GLP-1 receptor agonists and their effects on obesity management: A comprehensive review. Nature Reviews Endocrinology. https://pubmed.ncbi.nlm.nih.gov/39376859/
  7. Smith, J., & Johnson, R. (2023). The role of GLP-1 receptor agonists in fat metabolism and obesity: A systematic review. Journal of Metabolic Research, 15(3), 145–158. https://pmc.ncbi.nlm.nih.gov/articles/PMC10449217/
  8. Alba, M., & Lopez, M. (2021). GLP-1 receptor agonists: A promising strategy for the treatment of obesity and metabolic diseases. Frontiers in Cell and Developmental Biology, 9, 777026. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.777026/full
  9. DeFronzo, R. A., & Tripathy, D. (2016). Glucagon-like peptide-1 receptor agonists: A novel class of drugs for the treatment of type 2 diabetes. Journal of Clinical Endocrinology & Metabolism, 101(4), 1264–1273. https://pmc.ncbi.nlm.nih.gov/articles/PMC4818054/
  10. Seki, T., & Ohta, A. (2024). The therapeutic potential of GLP-1 receptor agonists in managing obesity and type 2 diabetes: A review of recent advances. Frontiers in Endocrinology, 15, 1379228. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1379228/full

Subscribe to our Newsletter

To receive an email when we go live and other information about our products and services, please leave your email above. To see how we use your email, please click here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.